{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:55:33Z","timestamp":1793973333613,"version":"4.8.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA127003"],"award-info":[{"award-number":["P50 CA127003"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA245257"],"award-info":[{"award-number":["K08CA245257"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.annonc.2024.12.011","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:06:53Z","timestamp":1734523613000},"page":"426-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma"],"prefix":"10.1016","volume":"36","author":[{"given":"L.","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"DiToro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Baiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Berchuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Walmsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Gordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Karasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Damjanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.P.","family":"Danysh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wehrenberg-Klee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Kambadakone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.D.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.T.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Leshchiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Parida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.V.","family":"Uboha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sootome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Bensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Friboulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Lennerz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Juric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2024.12.011_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.12.011_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib3","doi-asserted-by":"crossref","first-page":"v872","DOI":"10.1093\/annonc\/mdz394.027","article-title":"ClarIDHy: a global, phase 3, randomized, double-blind study of ivosidenib (IDO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation","volume":"30","author":"Abou-Alfa","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib4","article-title":"Precision medicine and immunotherapy have arrived for cholangiocarcinoma: an overview of recent approvals and ongoing clinical trials","volume":"7","author":"Karasic","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.annonc.2024.12.011_bib7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.annonc.2024.12.011_bib8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annonc.2024.12.011_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2024.12.011_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.annonc.2024.12.011_bib12","series-title":"WITHDRAWN: FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma","year":"2024"},{"key":"10.1016\/j.annonc.2024.12.011_bib13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMcpc2027092","article-title":"Case 8-2021: A 34-year-old woman with cholangiocarcinoma","volume":"384","author":"Goyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.12.011_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1593\/neo.121106","article-title":"The N550K\/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors","volume":"15","author":"Byron","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.annonc.2024.12.011_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib17","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib20","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.annonc.2024.12.011_bib21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2024.12.011_bib22","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma","volume":"11","author":"Cleary","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib23","article-title":"Oncogenic RAS drives resistance to pemigatinib in cholangiocarcinoma harboring a FGFR2 delins disrupting ligand binding","volume":"7","author":"Lim","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.6004\/jnccn.2021.7121","article-title":"Robust response to futibatinib in a patient with metastatic FGFR-addicted cholangiocarcinoma previously treated using pemigatinib","volume":"20","author":"Rengan","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.annonc.2024.12.011_bib25","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2024.12.011_bib26","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.annonc.2024.12.011_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.12.011_bib29","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.12.011_bib30","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","article-title":"Clinical value of liquid biopsy in patients with FGFR2 fusion-positive cholangiocarcinoma during targeted therapy","volume":"30","author":"Gonz\u00e1lez-Medina","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.12.011_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","article-title":"A\u00a0molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases","volume":"27","author":"Chen","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.annonc.2024.12.011_bib32","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1158\/1078-0432.CCR-19-3958","article-title":"Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer","volume":"26","author":"Mao","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.12.011_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/emmm.201000070","article-title":"Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine","volume":"2","author":"Dias-Santagata","year":"2010","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.annonc.2024.12.011_bib34","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for\u00a0targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2024.12.011_bib35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.annonc.2024.12.011_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.annonc.2024.12.011_bib37","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.annonc.2024.12.011_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neo.2015.03.004","article-title":"Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors","volume":"17","author":"Hovelson","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.annonc.2024.12.011_bib39","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib40","doi-asserted-by":"crossref","first-page":"25826","DOI":"10.18632\/oncotarget.25381","article-title":"Clinical validation of the Tempus xO assay","volume":"9","author":"Beaubier","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2024.12.011_bib41","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1038\/s41467-022-30380-x","article-title":"Automated next-generation profiling of genomic alterations in human cancers","volume":"13","author":"Keefer","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2024.12.011_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-020-00130-7","article-title":"Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy","volume":"4","author":"Recondo","year":"2020","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2024.12.011_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib45","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2024.12.011_bib46","doi-asserted-by":"crossref","first-page":"e1691","DOI":"10.1634\/theoncologist.2020-0274","article-title":"Revisiting MET: clinical characteristics and treatment outcomes of patients with locally advanced or metastatic, MET-amplified esophagogastric cancers","volume":"25","author":"Chaudhary","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2024.12.011_bib47","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1021\/ja042798i","article-title":"Effect of proline and glycine residues on dynamics and barriers of loop formation in polypeptide chains","volume":"127","author":"Krieger","year":"2005","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.annonc.2024.12.011_bib48","volume":"116","author":"Hartl","year":"1997"},{"key":"10.1016\/j.annonc.2024.12.011_bib49","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib52","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib54","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib55","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A\u00a0phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor Debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.12.011_bib56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2024.12.011_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.annonc.2024.12.011_bib58","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib59","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib60","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.12.011_bib61","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.12.011_bib62","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2024.12.011_bib63","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acschembio.5b00014","article-title":"Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles\u2019 heel of targeted therapy","volume":"10","author":"Sohl","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.annonc.2024.12.011_bib64","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib65","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2024.12.011_bib66","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.12.011_bib67","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2024.12.011_bib68","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2023.41.16_suppl.4009","article-title":"Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors","volume":"41","author":"Borad","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.12.011_bib69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/1535-7163.MCT-22-0012","article-title":"Tinengotinib (TT-00420), a novel spectrum-selective small-molecule kinase inhibitor, is highly active against triple-negative breast cancer","volume":"22","author":"Peng","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2024.12.011_bib70","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1093\/oncolo\/oyad338","article-title":"First-in-human phase I study of tinengotinib (TT-00420), a multiple kinase inhibitor, as a single agent in\u00a0patients with advanced solid tumors","volume":"29","author":"Piha-Paul","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2024.12.011_bib71","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","article-title":"Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer","volume":"13","author":"Facchinetti","year":"2023","journal-title":"Cancer Discov"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424049901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424049901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:13:34Z","timestamp":1762319614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424049901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0923753424049901"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.12.011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}